Abstract
The objective of the study was to design membrane-controlled transdermal therapeutic system (TTS) for trimetazidine. The optimization of (i) concentration of ethanol-water solvent system, (ii) HPMC concentration of drug reservoir and (iii) limonene concentration in 2% w/v HPMC gel was done based on the in vitro permeation of trimetazidine across excised rat epidermis. A limonene-based membrane-controlled TTS of trimetazidine was fabricated and evaluated for its in vivo drug release in rabbit model. The in vitro permeation of trimetazidine from water, ethanol and selected concentrations (25, 50 and 75% v/v) of ethanol-water co-solvent systems showed that 50% v/v of ethanol-water solvent system provided an optimal transdermal flux of 233.1±3.8 μg/cm2.h. The flux of the drug decreased to 194.1±7.4 μg/cm2.h on adding 2% w/v of HPMC to ethanolic (50% v/v ethanol-water) solution of trimetazidine. However, on adding selected concentrations of limonene (0, 2, 4, 6 and 8% w/v) to 2% w/v HPMC gel drug reservoir, the flux of the drug increased to 365.5±7.1 μg/cm2.h. Based on these results, 2% w/v HPMC gel drug reservoir containing 6% w/v of limonene was chosen as an optimal formulation for studying the influence of rate-controlling EVA2825 membrane and adhesive-coated EVA2825 membrane. The flux of the drug across EVA2825 membrane (mean thickness 31.2 μm) decreased to 285.8±2.2 μg/cm2.h indicating that the chosen membrane was effective as rate-controlling membrane. On applying an adhesive coat (mean thickness 10.2 μm) to EVA2825 membrane, the drug flux further decreased to 212.4±2.6 μg/cm2.h. However, the flux of the drug across adhesive-coated EVA2825 membrane-rat epidermis composite was 185.9±2.9 μg/cm2.h, which is about 2-times higher than the desired flux. The fabricated limonene-based TTS patch of trimetazidine showed a mean steady state plasma concentration of 71.5 ng/mL for about 14 h with minimal fluctuation when tested in rabbits. It was concluded from the investigation that the limonene-based TTS patch of trimetazidine provided constant drug delivery across the skin in rabbit model.
Keywords: Transdermal, TTS, trimetazidine, limonene, in vitro permeation, rat epidermis, in vivo release, rabbit
Current Drug Delivery
Title: Limonene Enhances the In Vitro and In Vivo Permeation of Trimetazidine Across a Membrane-Controlled Transdermal Therapeutic System
Volume: 5 Issue: 1
Author(s): Yellela S. Krishnaiah and Saleh M. Al-Saidan
Affiliation:
Keywords: Transdermal, TTS, trimetazidine, limonene, in vitro permeation, rat epidermis, in vivo release, rabbit
Abstract: The objective of the study was to design membrane-controlled transdermal therapeutic system (TTS) for trimetazidine. The optimization of (i) concentration of ethanol-water solvent system, (ii) HPMC concentration of drug reservoir and (iii) limonene concentration in 2% w/v HPMC gel was done based on the in vitro permeation of trimetazidine across excised rat epidermis. A limonene-based membrane-controlled TTS of trimetazidine was fabricated and evaluated for its in vivo drug release in rabbit model. The in vitro permeation of trimetazidine from water, ethanol and selected concentrations (25, 50 and 75% v/v) of ethanol-water co-solvent systems showed that 50% v/v of ethanol-water solvent system provided an optimal transdermal flux of 233.1±3.8 μg/cm2.h. The flux of the drug decreased to 194.1±7.4 μg/cm2.h on adding 2% w/v of HPMC to ethanolic (50% v/v ethanol-water) solution of trimetazidine. However, on adding selected concentrations of limonene (0, 2, 4, 6 and 8% w/v) to 2% w/v HPMC gel drug reservoir, the flux of the drug increased to 365.5±7.1 μg/cm2.h. Based on these results, 2% w/v HPMC gel drug reservoir containing 6% w/v of limonene was chosen as an optimal formulation for studying the influence of rate-controlling EVA2825 membrane and adhesive-coated EVA2825 membrane. The flux of the drug across EVA2825 membrane (mean thickness 31.2 μm) decreased to 285.8±2.2 μg/cm2.h indicating that the chosen membrane was effective as rate-controlling membrane. On applying an adhesive coat (mean thickness 10.2 μm) to EVA2825 membrane, the drug flux further decreased to 212.4±2.6 μg/cm2.h. However, the flux of the drug across adhesive-coated EVA2825 membrane-rat epidermis composite was 185.9±2.9 μg/cm2.h, which is about 2-times higher than the desired flux. The fabricated limonene-based TTS patch of trimetazidine showed a mean steady state plasma concentration of 71.5 ng/mL for about 14 h with minimal fluctuation when tested in rabbits. It was concluded from the investigation that the limonene-based TTS patch of trimetazidine provided constant drug delivery across the skin in rabbit model.
Export Options
About this article
Cite this article as:
Krishnaiah S. Yellela and Al-Saidan M. Saleh, Limonene Enhances the In Vitro and In Vivo Permeation of Trimetazidine Across a Membrane-Controlled Transdermal Therapeutic System, Current Drug Delivery 2008; 5 (1) . https://dx.doi.org/10.2174/156720108783330970
DOI https://dx.doi.org/10.2174/156720108783330970 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
Call for Papers in Thematic Issues
Advancements in Robotic and AI-based Drug Discovery and Delivery for Neurological Disorders
Neurological disorders, including Alzheimer's disease, Parkinson's disease, epilepsy, and brain tumors, pose significant challenges in drug delivery due to the blood-brain barrier's intricate structure and the complexity of neuronal networks. Traditional drug delivery methods often fall short in reaching therapeutic concentrations within the central nervous system, limiting treatment efficacy and ...read more
Electrospun Fibers as Drug Delivery Systems
In recent years, electrospun fibers have attracted considerable attention as potential platforms for drug delivery due to their distinctive properties and adaptability. These fibers feature a notable surface area-to-volume ratio and can be intentionally designed with high porosity, facilitating an increased capacity for drug loading and rendering them suitable for ...read more
Emerging Nanotherapeutics for Mitigation of Neurodegenerative Disorders
Conditions affecting the central nervous system (CNS) present a significant hurdle due to limited access of both treatments and diagnostic tools for the brain. The blood-brain barrier (BBB) acts as a barrier, restricting the passage of molecules from the bloodstream into the brain. The most formidable challenge facing scientists is ...read more
Extracellular vesicles as drug delivery systems
Extracellular vesicles (EVs) are membranous vesicles released from almost all types of cells into extracellular space. EVs are categorized into different types including exosome (~30-150 nm), microvesicle or microparticle (~100-1,000 nm), apoptotic body (~1,000-5,000 nm), and others produced by different mechanisms. Since EVs bear the molecules (e.g., specific lipids, carbohydrates, ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Is Galanin a Promising Therapeutic Resource for Neural and Nonneural Diseases?
Current Drug Targets Phase II Drug Metabolism and Individualized Drug Therapy: A Focus on Functional Genetic Variation in UDP-Glucuronosyltransferases
Current Pharmacogenomics and Personalized Medicine Targeting of NF-kappaB Signaling Pathway, other Signaling Pathways and Epigenetics in Therapy of Multiple Myeloma
Cardiovascular & Hematological Disorders-Drug Targets Polymersomes in Nanomedicine - A Review
Current Nanoscience Statins and Protein Prenylation in Cancer Cell Biology and Therapy
Anti-Cancer Agents in Medicinal Chemistry The Effect of Viola Odorata L. Oil for Fever in Children: A Randomized Triple-blinded Placebo-controlled Clinical Trial
Current Drug Discovery Technologies Effects of Kojic Acid-mediated Sonodynamic Therapy as a Matrix Metalloprotease-9 Inhibitor against Oral Squamous Cell Carcinoma: A Bioinformatics Screening and <i>In Vitro</i> Analysis
Current Drug Discovery Technologies The Role of Cellular Senescence During Vascular Calcification: A Key Paradigm in Aging Research
Current Aging Science New Scope of Targeted Therapies in Lung Carcinoma
Mini-Reviews in Medicinal Chemistry Cornea: Window to Ocular Immunology
Current Immunology Reviews (Discontinued) Traditional Herbal Medicines, Newer Herbs and Other Novel Approaches Integrated in Herbal Medicine for Atopic Dermatitis-A Narrative Review
Current Drug Therapy Pharmaceutical and Biomedical Applications of Interpenetrating Polymer Network
Current Drug Therapy HLA-I Antigen Presentation and Tapasin Influence Immune Responses Against Malignant Brain Tumors-Considerations for Successful Immunotherapy
Anti-Cancer Agents in Medicinal Chemistry Role of Vitamin D in the Pathophysiology and Treatment of Type 2 Diabetes
Current Diabetes Reviews Dietary Interventions for Atopic Disorders
Current Pharmaceutical Design Nutrition, Brain Aging, and Alzheimers Disease
Current Nutrition & Food Science Role of NFAT5 in Inflammatory Disorders Associated with Osmotic Stress
Current Genomics Different Concepts of Drug Delivery in Disease Entities
Mini-Reviews in Medicinal Chemistry Recent Developments in Patents Targeting Toll-Like Receptor Genes
Recent Patents on DNA & Gene Sequences IL-10 Producing Regulatory B Cells in Mice and Humans: State of the Art
Current Molecular Medicine